Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M416Revenue (TTM) $M35.9Net Margin (%)-293.0Altman Z-Score-7.5
Enterprise Value $M341EPS (TTM) $-0.4Operating Margin %-280.2Piotroski F-Score1
P/E(ttm)--Beneish M-Score-3.2Pre-tax Margin (%)-293.0Higher ROA y-yN
Price/Book11.110-y EBITDA Growth Rate %-28.3Quick Ratio3.0Cash flow > EarningsY
Price/Sales11.55-y EBITDA Growth Rate %-23.1Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-35.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-128.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M243ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2016-03-31 Sold Out $1.41 - $1.97
($1.61)
$ 1.716%Sold Out0
ARNAKen Fisher 2015-12-31 Add$1.7 - $2.4
($2.04)
$ 1.71-16%Add 0.91%11,100
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 1.71-67%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 1.711%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 1.718%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
White Christine AnnaDirector 2016-06-13Sell18,728$1.99-17.09view
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-63.25view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-67view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-73.64view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-69.95view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-71.79view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-71.79view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-76.6view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-76.43view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-73.85view

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 16 2016
Arena Pharmaceuticals Hires Kevin Lind As CFO Jun 15 2016
Here’s Why Traders Are Buzzing about These Five Stocks Jun 15 2016
Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer Jun 15 2016
Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer Jun 15 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Jun 13 2016
Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug... Jun 13 2016
Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug... Jun 13 2016
Orexigen Stock Gains More than 50% on Markman Hearing Jun 09 2016
Antidote Company's Valuation Misaligned With Growing Crisis Jun 06 2016
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? Jun 01 2016
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : June... Jun 01 2016
How Hedge Funds Traded Marijuana Stocks in Q1 May 28 2016
ETF’s with exposure to Arena Pharmaceuticals, Inc. : May 26, 2016 May 26 2016
ARENA PHARMACEUTICALS INC Financials May 18 2016
The 2017 Annual Shareholders’ Meeting of GF will take place at the IWC Arena in Schaffhausen May 18 2016
ETF’s with exposure to Arena Pharmaceuticals, Inc. : May 16, 2016 May 16 2016
Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q1, 2016 By the Numbers May 13 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)